pravastatin has been researched along with Diabetic Angiopathies in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Ahotupa, M; Janatuinen, T; Knuuti, J; Nuutila, P; Raitakari, OT; Rönnemaa, T; Toikka, JO | 1 |
| Isley, WL | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Bouchier-Hayes, DJ; Casey, RG; Fitzgerald, P; Joyce, M; Moore, K; Thompson, C | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Jacobson, TA; Walker, DB | 1 |
| Fujii, T; Kuwano, H; Onimaru, M; Sueishi, K; Yonemitsu, Y | 1 |
| Kamata, K; Kasuya, Y; Suenaga, H; Sugiura, M | 1 |
| Chisholm, DJ; Greenfield, JR | 1 |
| Jackson, G | 1 |
| Dumont, AS; Dumont, RJ; Fedak, PM; Hyndman, ME; Kassell, NF; Sutherland, GR; Verma, S | 1 |
2 review(s) available for pravastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Initiating statins in the elderly: the evolving challenge.
Topics: Aged; Clinical Trials as Topic; Coronary Disease; Diabetic Angiopathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Primary Prevention; Safety; Stroke | 2008 |
4 trial(s) available for pravastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes.
Topics: Adult; Coronary Circulation; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Dipyridamole; Double-Blind Method; Female; Glucose Clamp Technique; Heart; Hemodynamics; Humans; Hyperinsulinism; Lipoproteins, LDL; Male; Oxidation-Reduction; Positron-Emission Tomography; Pravastatin; Retinal Vessels | 2004 |
Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes.
Topics: Adult; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Pravastatin; Stroke Volume; Vasodilation | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
10 other study(ies) available for pravastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
Pravastatin normalizes ET-1-induced contraction in the aorta of type 2 diabetic OLETF rats by suppressing the KSR1/ERK complex.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pravastatin; Protein Kinases; Protein Phosphatase 2; Rats; Rats, Inbred OLETF; Signal Transduction; src-Family Kinases; Time Factors; Vasoconstriction; Vasoconstrictor Agents | 2012 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
What did PROVE-IT prove?
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy | 2004 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression.
Topics: Animals; Becaplermin; Blood Glucose; Cells, Cultured; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Foot; Enzyme Inhibitors; Genetic Therapy; Glycation End Products, Advanced; Hindlimb; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet-Derived Growth Factor; Pravastatin; Proto-Oncogene Proteins c-sis; Quinolines; Regional Blood Flow; Signal Transduction; Time Factors; Up-Regulation | 2008 |
[Effect of cholestyramine on angiopathies in cholesterol-fed mice and diabetic mice].
Topics: Animals; Anticholesteremic Agents; Cholesterol, Dietary; Cholestyramine Resin; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Hypercholesterolemia; Male; Mice; Mice, Inbred ICR; Pravastatin; Vascular Diseases; Vasodilation | 1995 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Hypertension; Hypoglycemic Agents; Metformin; Myocardial Ischemia; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2000 |
Diabetes, statins and cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Humans; Hyperlipidemias; Pravastatin | 2001 |
Improvement of endothelial function in insulin-resistant carotid arteries treated with pravastatin.
Topics: Animals; Carotid Stenosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Hypertension; Insulin Resistance; Male; Nitric Oxide; Pravastatin; Rats; Rats, Sprague-Dawley; Risk Factors; Stroke; Vascular Resistance | 2001 |
Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Markov Chains; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Sulfonylurea Compounds; United States | 2002 |